PD-1 Inhibitor 16 (extracted from Patent (compound 16, ref 1)) is an orally bioavailable small molecule peptidomimetic inhibitor of the immune checkpoint regulatory proteins PD-I/PD-L1 (programmed cell death -1/programmed cell death ligand-1) interaction, with signaling activity in cancer cells, and is currently being evaluated as a potential negative immune checkpoint regulatory and antineoplastic agent.

KEYWORDS: PD-1 Inhibitor 16 | PD-1 inhibitor | PD1 Inhibitor 16 | PD 1 Inhibitor 16 | CT-PD1-16 | CAS [2005454-12-4] | T-Cell activity | PD-1 | Inhibitor | Proteins